Biotech pharma

64x Bio

Website

The future of medicine is taking shape, but scaling it remains a challenge. Some of the biggest breakthroughs in next generation therapies are being held back by manufacturing constraints. The science is moving fast, but the infrastructure is still catching up. Our VectorSelect platform is designed to unlock the scale these therapies need to sur

Founded 2017Origin source ↗Checked 2026-09-15

Overview

The future of medicine is taking shape, but scaling it remains a challenge. Some of the biggest breakthroughs in next generation therapies are being held back by manufacturing constraints. The science is moving fast, but the infrastructure is still catching up.

Our VectorSelect platform is designed to unlock the scale these therapies need to survive. We combine massively parallelized screens with computational insights to engineer high yield cell lines and production technologies — accelerating the manufacturing of advanced therapies from the inside out.

Company description As recorded 2026-11-08
LinkedIn About
Biotech pharmaInfrastructureBusinessesEnterpriseLicensing

Founders & team

Previously 64-X, 64-x

Company history As recorded 2026-11-08

Lexi Rovner

Founder/CEO

Lexi Rovner, PhD is the CEO & co-founder of 64x Bio, a spinout of Harvard Medical School and the Wyss Institute. Lexi completed her PhD at Yale University and her postdoctoral work in George Church’s lab at Harvard Medical School, where she co-founded the company alongside George, Pam Silver, Jeff Way, and David Thompson. Lexi is a Y Combinator alum, a 2022 Endpoints 20 under 40 Next-Generation Biotech Leader, and a 2022 Bloomberg New Economy Catalyst Awardee.

LinkedIn
Founder profile As recorded 2026-09-15
25team members reported
Source-reported As recorded 2026-09-15

Founded 2017 · Source

News & product activity

Sources & observations

Y Combinator

Profile depthverified profile
Website observationwebsite reachable
Last website check2026-11-11
Location · source statedSan Francisco, CA, USA
Pricing evidenceNo pricing page confirmed
Maturity: Not assessed · 3 of 6 areas documented

Source-based assessment · automated evidence rules

The homepage contains prelaunch or closure language; availability needs review.

Maturity is an evidence-based assessment, not a success rating. It may understate the current stage where evidence is limited. Coverage records documented areas, not a complete or independently audited company history.

Stage definitions
independent websitesource corroborationreachable websitedescriptive evidenceclassified market and modelsourced peoplesourced founding year
startup.observe Directory coverage · Sources & method